AstraZeneca's ($AZN) gout treatment lesinurad may have a checkered efficacy record, but the European Medicines Agency (EMA) has accepted the company's application for the drug--meaning it still has a chance to become the blockbuster the British pharma giant had hoped for. Even if it does pass muster with regulators, however, lesinurad still faces hurdles ahead: For one, AZ could run into trouble convincing payers to shell out for a new therapy without clear evidence of improvement over the 50-year-old generic allopurinol, and Takeda and Ipsen's ($IPN) febuxostat, approved in 2009. More